文献速递产科母胎医学

ASPRE试验:符合ACOG与NICE标准的患者中早产子痫前期的发生率及FMF算法风险分层

ASPRE trial: incidence of preterm pre-eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm.
PubMed 文献 · Ultrasound Obstet Gynecol · 2018-05-03

该研究为ASPRE试验的二次分析,纳入34573例单胎妊娠孕妇,在孕11-13周用FMF算法前瞻性筛查早产子痫前期。结果显示,符合ACOG或NICE标准但FMF算法筛查阴性的孕妇,早产子痫前期风险降至背景水平或以下。

要点

  • 符合ACOG标准者早产子痫前期发生率为0.97%,FMF筛查阳性亚组为4.80%,阴性亚组为0.25%。
  • 符合NICE高危标准者发生率为5.17%,FMF筛查阳性亚组为8.71%,阴性亚组为0.65%。
  • 符合NICE中危标准者发生率为1.74%,FMF筛查阳性亚组为4.91%,阴性亚组为0.42%。

核心结论

  • 符合ACOG或NICE标准但FMF算法筛查阴性的孕妇,早产子痫前期风险降至背景水平或以下,结果支持基于个性化风险的筛查方法。

研究设计与样本

  • ASPRE研究的二次分析,纳入34573例单胎妊娠且于≥24周分娩的孕妇,于孕11-13周用FMF算法(结合母体因素与生物标志物)前瞻性筛查早产子痫前期。

主要发现

  • 239例(0.7%)发生早产子痫前期;22287例(64.5%)符合至少一项ACOG标准,其中早产子痫前期发生率为0.97%(95%CI 0.85-1.11%)。
  • 符合至少一项NICE高危标准者1392例(4.0%),早产子痫前期发生率为5.17%(95%CI 4.13-6.46%)。
  • 符合至少两项NICE中危标准者2360例(6.8%),早产子痫前期发生率为1.74%(95%CI 1.28-2.35%)。

关键数值与推荐

  • ACOG标准人群:FMF筛查阳性亚组早产子痫前期发生率4.80%(95%CI 4.14-5.55%),阴性亚组0.25%(95%CI 0.18-0.33%),阴性相对阳性的相对发生率为0.051(95%CI 0.037-0.071)。
  • NICE高危标准人群:FMF筛查阳性亚组发生率8.71%(95%CI 6.93-10.89%),阴性亚组0.65%(95%CI 0.25-1.67%),相对发生率为0.075(95%CI 0.028-0.205)。
  • NICE中危标准人群:FMF筛查阳性亚组发生率4.91%(95%CI 3.54-6.79%),阴性亚组0.42%(95%CI 0.20-0.86%),相对发生率为0.085(95%CI 0.038-0.192)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the incidence of preterm pre-eclampsia (PE) in women who are screen positive according to the criteria of the National Institute for Health and Care Excellence (NICE) and the American College of Obstetricians and Gynecologists (ACOG), and compare the incidence with that in those who are screen positive or screen negative by The Fetal Medicine Foundation (FMF) algorithm. METHODS: This was a secondary analysis of data from the ASPRE study. The study population consisted of women with singleton pregnancy who underwent prospective screening for preterm PE by means of the FMF algorithm, which combines maternal factors and biomarkers at 11-13 weeks' gestation. The incidence of preterm PE in women fulfilling the NICE and ACOG criteria was estimated; in these patients the incidence of preterm PE was then calculated in those who were screen negative relative to those who were screen positive by the FMF algorithm. RESULTS: A total of 34 573 women with singleton pregnancy delivering at ≥ 24 weeks' gestation underwent prospective screening for preterm PE, of which 239 (0.7%) cases developed preterm PE. At least one of the ACOG criteria was fulfilled in 22 287 (64.5%) pregnancies and the incidence of preterm PE was 0.97% (95% CI, 0.85-1.11%); in the subgroup that was screen positive by the FMF algorithm the incidence of preterm PE was 4.80% (95% CI, 4.14-5.55%), and in those that were screen negative it was 0.25% (95% CI, 0.18-0.33%), with a relative incidence in FMF screen negative to FMF screen positive of 0.051 (95% CI, 0.037-0.071). In 1392 (4.0%) pregnancies, at least one of the NICE high-risk criteria was fulfilled, and in this group the incidence of preterm PE was 5.17% (95% CI, 4.13-6.46%); in the subgroups of screen positive and screen negative by the FMF algorithm, the incidence of preterm PE was 8.71% (95% CI, 6.93-10.89%) and 0.65% (95% CI, 0.25-1.67%), respectively, and the relative incidence was 0.075 (95% CI, 0.028-0.205). In 2360 (6.8%) pregnancies fulfilling at least two of the NICE moderate-risk criteria, the incidence of preterm PE was 1.74% (95% CI, 1.28-2.35%); in the subgroups of screen positive and screen negative by the FMF algorithm the incidence was 4.91% (95% CI, 3.54-6.79%) and 0.42% (95% CI, 0.20-0.86%), respectively, and the relative incidence was 0.085 (95% CI, 0.038-0.192). CONCLUSION: In women who are screen positive for preterm PE by the ACOG or NICE criteria but screen negative by the FMF algorithm, the risk of preterm PE is reduced to within or below background levels. The results provide further evidence to support the personalized risk-based screening method that combines maternal factors and biomarkers. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Poon LC, Rolnik DL, Tan MY, et al. ASPRE trial: incidence of preterm pre-eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm. Ultrasound Obstet Gynecol. 2018. PMID: 29380918. doi:10.1002/uog.19019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。